Ipamorelin vs GHRP 6: compare GH release, appetite, cortisol, and prolactin effects, plus dosing, safety, and FDA status for each research peptide.
Ipamorelin and GHRP-6 are both ghrelin mimetics that stimulate growth hormone release, but they behave very differently in the body. Ipamorelin is the more selective of the two, producing a growth hormone pulse with little effect on appetite, cortisol, or prolactin. GHRP-6 is an older, broader-acting peptide that drives stronger hunger and measurable shifts in several hormones.
What Ipamorelin and GHRP-6 Have in Common
Both compounds belong to the growth hormone secretagogue family and bind the ghrelin receptor, also known as GHS-R1a. Activating that receptor signals the pituitary to release growth hormone, which is why the two peptides are compared so often.
Shared features include:
- Both are synthetic peptides sold as research chemicals rather than prescription drugs.
- Both produce pulsatile growth hormone release instead of a steady level.
- Both are frequently studied alongside a GHRH analog such as CJC-1295 or sermorelin.
- Neither is FDA-approved for human use in the United States.
Ipamorelin vs GHRP-6: Side-by-Side Comparison
The debate often shortened to ipamorelin vs ghrp-6 comes down to selectivity versus raw output. The table below summarizes the differences that matter most in research settings.
| Factor | Ipamorelin | GHRP-6 |
|---|---|---|
| Peptide class | Pentapeptide ghrelin mimetic | Hexapeptide ghrelin mimetic |
| Growth hormone release | Moderate, clean pulse | Strong, dose-dependent |
| Appetite effect | Minimal to mild | Marked hunger increase |
| Cortisol | Little to no rise | Measurable rise at higher doses |
| Prolactin | Little to no rise | Measurable rise at higher doses |
| Gastric emptying | Mild effect | Strongly accelerated |
| Typical research amount | About 100-200 mcg per dose | About 100-300 mcg per dose |
Dose ranges above reflect amounts reported in research literature, not medical recommendations. No approved human dose exists for either compound.
Why Selectivity Matters: Appetite, Cortisol, and Prolactin
Ipamorelin was designed to separate growth hormone release from the other effects of ghrelin. Animal studies found that it raised growth hormone without meaningfully raising ACTH, cortisol, prolactin, or aldosterone, which is why it is often described as a clean secretagogue.
GHRP-6 hits the same receptor but triggers a broader response. It is well known for increasing hunger, sometimes dramatically, and it can raise cortisol and prolactin, particularly at higher amounts. Those effects are not automatically dangerous in short-term research, but they are part of the trade-off.
GHRP-6 is generally reported to stimulate appetite more strongly than ipamorelin, which makes it a poor fit for anyone trying to manage hunger.
Many readers searching ipamorelin vs sermorelin are really asking whether a selective ghrelin mimetic or a GHRH analog is the better starting point. Ipamorelin and sermorelin act on different receptors, so their release patterns and side effect profiles are not identical.
Dosing and Stacking in Research Protocols
Researchers often combine a GHRH analog with a ghrelin mimetic to amplify the growth hormone pulse. Stack details, including cjc-1295 with dac vs ipamorelin, usually depend on whether a long-acting or short-acting profile is preferred.
Combination questions such as cjc-1295 ipamorelin vs tesamorelin tend to focus on whether two compounds outperform one. Tesamorelin is a GHRH analog with a different mechanism, so it is not a direct substitute for either peptide in this comparison.
Fat-loss compounds belong to a separate conversation, since aod 9604 vs cjc 1295 targets lipolysis and growth hormone release through distinct pathways. Mixing categories can make a protocol harder to interpret, not easier.
How People Choose Between the Two
For research purposes, ipamorelin is usually chosen when a clean growth hormone signal and minimal appetite change are the priorities. GHRP-6 is chosen when stronger growth hormone output and increased appetite are the goals, or when cost and availability matter more.
Oral and non-peptide routes also come up, which is why ipamorelin vs mk-677 is such a common search. MK-677 is an oral ghrelin receptor agonist rather than a peptide, so its dosing schedule, duration of action, and side effect profile differ from injected compounds.
Safety, Legality, and FDA Status
Ipamorelin is not FDA-approved for human use in the United States, and neither is GHRP-6. Both are sold as research chemicals, and products labeled for research use are not held to the same purity and sterility standards as prescription medications.
Reported side effects of GHRP-6 include intense hunger, water retention, and possible increases in cortisol and prolactin. Ipamorelin is generally described as better tolerated in those areas, though injection-site reactions and headaches are still reported.
Anyone considering these compounds should speak with a licensed healthcare professional. Self-treating with research peptides carries legal and health risks, and bloodwork monitoring is typically recommended in clinical settings.
Frequently Asked Questions
Is ipamorelin stronger than GHRP-6?
GHRP-6 generally produces a larger growth hormone release than ipamorelin, but it also raises hunger, cortisol, and prolactin more noticeably. Ipamorelin creates a smaller, cleaner pulse with fewer hormonal side effects. Which one is "stronger" depends on whether you are measuring total growth hormone output or selectivity.
Does GHRP-6 increase appetite more than ipamorelin?
Yes. GHRP-6 is well known for causing a strong, sometimes sudden increase in hunger, while ipamorelin has minimal to mild effect on appetite. That difference is one of the main reasons researchers separate the two compounds in comparisons. Anyone trying to control caloric intake usually looks at GHRP-6 as the harder option to manage.
Are ipamorelin and GHRP-6 FDA-approved?
Neither ipamorelin nor GHRP-6 is FDA-approved for human use in the United States. Both are sold as research chemicals, and their legal status can vary by state and by how they are marketed. A licensed healthcare professional is the right source for guidance on any growth hormone-related treatment.
This page provides educational research information and does not replace medical advice, diagnosis, or treatment.